QSP

(M-011) Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients

(M-013) QSP Model of Nivolumab in Combination with Bispecific T Cell Engagers predicts Enhanced Anti-Tumor Immunity

(M-014) Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study

(M-015) Hybrid MBMA-QSP Model Predicts T Cell Engager Plus Cereblon E3 Ligase Modulatory Drugs Combination Outcomes As A Function Of Prior Therapies In Relapsed/refractory Multiple Myeloma

(M-017) Comparative Sensitivity Analysis of Semi-mechanistic and QSP Models of Humoral Response Following Vaccination

(M-019) In silico validation of MARIPOSA trial outcomes in EGFR‑mutated NSCLC using a QSP‑based disease model integrated with a newly implemented lazertinib drug model

(M-022) A multi-model strategy in R to address cytopenia

(M-035) Predicting Improved Weaning Strategies for Mechanical Ventilation with a Physiologically-Based Mechanistic Model

(M-037) A quantitative systems pharmacology model of felzartamab, an anti-CD38 antibody, to link immune cell and pharmacodynamic responses in immune mediated diseases

(M-057) Quantitative Systems Pharmacology Modeling to Support First-in-Human Dose Selection for a CD3 Bispecific Antibody in B-Cell Lymphoma and Renal Cell Carcinoma

(M-058) Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection

(M-059) Investigating the Role of Epithelial Barrier Function in Inflammatory Bowel Disease with Mechanistic Modeling

(M-063) Quantitative Model of the Ocular Immune Response to Seasonal Allergic Conjunctivitis

(M-064) Mechanistic Insights Uncover Novel Therapeutic Targets in Cardiac Hypertrophy

(M-076) Machine learning approach links QSP virtual populations with key lesion types and clinical scoring in hidradenitis suppurativa

(M-077) Ocular Pharmacokinetic/Pharmacodynamic Modeling of Drug Release from Single- and Bi-Layered Polymeric Microspheres for Retinal Conditions

(M-078) Combining Mechanistic Modeling and Deep Learning for Predicting Survival Probabilities in Oncology

(M-084) Modeling Blood Urea Nitrogen (urea) Dynamics to Estimate Dialysis Adequacy

(M-089) Identifying an optimal dose range for clinical development of BT7480 using a fit-for-purpose quantitative system pharmacology (QSP) modeling

(M-090) Pharmacoequivalence vs Bioequivalence: A role for MIDD analysis in bioequivalence studies

(M-092) QSP modeling to inform key clinical dosing regimen decisions for an engineered IL15 cytokine Efbalropendekin alfa in patients with solid tumors

(M-098) Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling

(M-099) Case Study: Parameter Estimation of an NLME-QSP Model

(M-100) Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

(S-012) A Minimal-Quantitative Systems Pharmacology Model for Dual-Targeting Bispecific T Cell Modulators in Immuno-Oncology for Solid Tumors

(S-013) Proteosis-Targeting Chimera Efficacy Prediction Using a Deep-Learning–QSP Model

(S-017) Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model

(S-018) Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model

(S-019) Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement

(S-035) Mechanistic insights on diverse in vivo tumor efficacy outcomes for bispecific T-cell engagers using a quantitative systems pharmacology model

(S-036) Modeling for prediction of CCR8 receptor occupancy in human tumor tissues after dosing of S-531011, a humanized anti-CCR8 monoclonal antibody

(S-049) Understanding PK/PD relationship of CD19 CAR-T (BMS-986353) in Systemic Lupus Erythematosus (SLE) using a mechanistic quantitative pharmacology framework

(S-050) Quantitative systems modeling of inflammation and coagulation abnormalities induced by pathogen infection

(S-061) Insights into Guide-Effector Antigen Interaction for Bispecific Antibody Design Using a Mechanistic Model

(S-062) Development of a Quantitative Systems Pharmacology Model for Hepatitis B Virus Infection and Hepatitis D Virus Co-Infection.

(S-063) A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations

(S-066) Right-Sizing Models: A Model Reduction Approach Applied to Models of the Treatment of Solid Tumors by Protein Degraders

(S-067) Moment closure for uncertainty propagation in QSP models

(S-078) A Translational QSP Modeling Framework Demonstrates Tissue-Level Pharmacokinetics Do Not Predict the Clinical Efficacy of FTC/TDF PrEP

(S-085) Investigating the Role of Estradiol in Oxidative Stress in Health and Disease: A Mechanistic Model

(S-086) QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform

(S-087) A Quantitative Systems Pharmacology (QSP) Model Platform to Study the Impact of Intra-tumoral Heterogeneity on Antibody-Drug Conjugate (ADC) Treatment Efficacy

(S-092) Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies

(S-094) Development of a Quantitative Systems Pharmacology (QSP) Model of the Complement System Capturing Crosstalk Between the Classical and Alternative Pathways

(S-095) A Julia Package for Traceable and Reproducible Models in Quantitative Systems Pharmacology

(T-005) Bench to bedside modelling of mRNA encoding IgG using a multiscale mechanistic PK-PD model: A case study with anti-claudin 18.2

(T-007) Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs

(T-008) Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS

(T-009) Bridging Preclinical Data and Human Dose Selection for ADCs: Lessons from Approved Molecules

(T-012) Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations

(T-013) Adaptable PBPK-QSP gene therapy model applied to i.v. administration of AAV-2 across different species

(T-034) In silico model of hypertrophic cardiomyopathy caused by MYBPC3 mutation predicted key drivers of cardiomyocyte morphology

(T-035) Integrating Age-Related Immune Differences to Enhance Vaccine Response Predictions of a Quantitative Systems Pharmacology (QSP) Model

(T-051) Efficient Generation of Plausible Virtual Populations Using Machine Learning Surrogate Classification Models

(T-052) Application of Neural ODEs for Agnostic Inference of Feedback Mechanism Structure in QSP Models

(T-053) QSP Modeling of Potassium Regulation in Rare and Complex Cardiorenal Disorders

(T-064) Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity

(T-066) QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations

(T-067) Mathematical Modeling of Tumor Response to Fibroblast Activation Protein (FAP)-Targeted Radiopharmaceutical Therapy

(T-075) Mechanistic Modeling and Unsupervised Learning Reveal Drivers of Inter-Individual Variability in COVID-19 Vaccine-Induced Immunity

(T-076) Virtual clinical trial simulations across treatment lines using a QSP model of CDK inhibitors in breast cancer patients

(T-089) A Framework for Developing a Virtual Murine Cohort: Applications to Adoptive Cell Therapy in Bladder Cancer

(T-090) Development and validation of a model-based framework to inform the preclinical to clinical translation of Mpro inhibitor antivirals

(T-091) gQSPTwin: A MATLAB-Based Application for Automation and Standardization of the QSP Digital Twin Generation Workflow

(T-092) Mechanistic Modeling of Bispecific Antibody Combination Therapy to Optimize TumorKilling in Cancer Immunotherapy

(T-096) Enabling Earlier Predictions of Hepatotoxic Risk with Quantitative Structure-Activity Relationship-Machine Learning (QSAR-ML) and Quantitative Systems Toxicology (QST) Models

(T-114) Open-Source Modeling of Anti-Tuberculosis Drug-Induced Cardiac Risks for Safe Dose Prediction